Factors affecting growth hormone treatment in short stature children born small for gestational age in China: a single-centre, real-world study
Endocrine · 2024
DOI: 10.1007/s12020-024-04009-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine, 2024. Verfasst von Li Xi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Children's Hospital of Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Human Growth Hormone, Infant, Small for Gestational Age, Body Height, Growth Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE: The study aimed to evaluate the factors influencing recombinant human growth hormone (rhGH) treatment in Chinese children with short stature born small for gestational age (SGA). METHODS: A single-centre, real-world retrospective study was conducted in short stature children born SGA in China. Outcomes were observed at 6, 12, 18, 24, 30, and 36 months. Outcome measures included height standard deviation score (HTSDS), height, growth velocity (GV), and change of HTSDS (ΔHTSDS). The study used the generalized estimating equation (GEE) to identify potential influencing factors, such as rhGH treatment duration, age at rhGH initiation, sex, 11p15 hypomethylation, GH secretion, and birth weight. A subgroup analysis was conducted to investigate the impact of 11p15 hypomethylation related to SGA or impaired GH secretion. RESULTS: Of all 101 SGA patients included in the screening, 41 were eligible for inclusion in the study. The mean age at rhGH initiation was 5.6 ± 2.4 years. The results of the GEE analysis showed a significant association between time after rhGH initiation and HTSDS, height, GV, and ΔHTSDS. GV increased after treatment, with the highest increase observed in the first six months. Additionally, the study found negative correlations between 11p15 hypomethylation and GV, as well as between birth weight and both GV and ΔHTSDS. The study found a positive correlation between impairment in GH secretion and both GV and ΔHTSDS. No statistically significant difference was observed in the comparison of GV or ΔHTSDS between the initiation age of GH treatment and 11p15 hypomethylation. After 24 and 30 months of rhGH treatment, patients with impaired GH secretion had significantly higher ΔHTSDS scores. CONCLUSIONS: In short stature Chinese children born SGA, those without SGA-related 11p15 hypomethylation or with impaired GH secretion showed better response to rhGH treatment. These findings highlight the importance of pre-treatment evaluation, including genetic and endocrine assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Children's Hospital of Fudan University, Shanghai, China.
- Medical Affairs, GeneScience Pharmaceuticals Co., Ltd. (GenSci), Shanghai, China.
- Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Children's Hospital of Fudan University, Shanghai, China. luofh@fudan.edu.cn.
ORCID-Profile: Feihong Luo
Zitieren
APA
Xi, L., Cheng, R., He, Y., Li, X., Ni, J., Wu, J., Xu, Z., & Luo, F. (2024). Factors affecting growth hormone treatment in short stature children born small for gestational age in China: a single-centre, real-world study. Endocrine. https://doi.org/10.1007/s12020-024-04009-6
Vancouver
Xi L, Cheng R, He Y, Li X, Ni J, Wu J, et al. Factors affecting growth hormone treatment in short stature children born small for gestational age in China: a single-centre, real-world study. Endocrine. 2024. doi:10.1007/s12020-024-04009-6
BibTeX
@article{Xi2024,
author = {Xi, Li and Cheng, Ruoqian and He, Yingkai and Li, Xiaojing and Ni, Jinwen and Wu, Jing and Xu, Zhenran and Luo, Feihong},
title = {Factors affecting growth hormone treatment in short stature children born small for gestational age in China: a single-centre, real-world study},
journal = {Endocrine},
year = {2024},
doi = {10.1007/s12020-024-04009-6}
}
EUVIMED